White House withdraws Heidi Overton’s FDA nomination before Senate vote

The administration withdrew the New Mexico physician’s nomination on November 17, 2026, after reports of insufficient Senate support and Republican concerns about her positions on vaccines, abortion medication and vaping.

The White House withdrew Heidi Overton’s nomination to lead the Food and Drug Administration on November 17, 2026, a day before the Senate committee handling the nomination was scheduled to vote. News reports attributed the decision to a lack of support among senators, including wavering Republicans.

The Senate Health, Education, Labor and Pensions Committee’s records confirm that the committee received a presidential withdrawal message. Its notice had scheduled a vote for November 18, meaning Overton’s nomination will not proceed to that vote.

A nomination amid policy disputes

President Donald Trump selected Overton in August 2026. The Senate record identifies her as a physician from New Mexico and names her as the nominee for FDA commissioner, succeeding Martin Makary. She was serving as an official on the White House Domestic Policy Council.

Her nomination put a White House policy aide forward to lead an agency dealing with disputes over vaccines, abortion medication and drug approvals, Reuters reported. The Guardian described Overton as an abortion opponent, but the available reporting does not establish that this was the administration’s reason for withdrawing her nomination.

Overton appeared before the Senate committee on September 24. Senators questioned her about vaccines and mifepristone, the abortion medication, according to Reuters. In the days before the withdrawal, CBS and the Washington Post reported that lawmakers had also raised questions about her positions or actions concerning those issues and vaping.

Support concerns before the scheduled vote

The Associated Press and Axios reported that the White House acted because Overton lacked sufficient congressional support. CBS had reported skepticism among Republicans on the HELP Committee, including uncertainty from its chair, Sen. Bill Cassidy. Those accounts point to difficulties assembling votes, but the committee record confirms the withdrawal without providing a detailed official explanation for the decision.

The distinction matters: reported concerns among senators help explain the timing, but they are not the same as a formal statement of the White House’s internal reasoning. The available evidence links the withdrawal to a vote-count problem and lawmakers’ questions, without establishing one concern as the decisive cause.

What happens next

With the nomination withdrawn, the administration will need another nominee to lead the FDA. The committee’s scheduled November 18 vote will not take place on Overton’s nomination. The supplied evidence does not identify a replacement or establish what approach a successor might take on the policy disputes that arose during Overton’s confirmation process.

Reuters described the agency as facing staff losses and low morale, alongside disputes over vaccines, abortion medication and drug approvals. That context gives the leadership vacancy significance, but the available information does not show how the withdrawal will affect the agency’s work or when a new nominee may be selected.

The Beacon Briefing

Stay informed. See further.

The stories that matter, the context behind them. Get Beacon’s essential reporting in your inbox.

Placeholder signup form · Connect your newsletter provider to activate.